Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 5/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL586866 | 0.91 | KMT2A (0.56) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL586865 | 0.91 | KMT2A (0.56) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL4657877 | 0.88 | HPGD (0.52) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL6105130 | 0.87 | HPGD (0.60) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL31352467 | 0.85 | HPGD (0.55) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL16604392 | 0.84 | HPGD (0.60) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL895798 | 0.84 | HPGD (0.54) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL22105680 | 0.83 | HPGD (0.43) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL1002397 | 0.83 | HPGD (0.59) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL20353737 | 0.83 | HPGD (0.59) | HPGDRECQLPTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025051102-A1 | DEUTERATED TETRACYCLIC DERIVATIVE AND USE THEREOF | 浙江我武翼方药业有限公司 | 2025-03-13 | — | — | WO | disclosed |
| CN-119591611-A | Deuterated tetracyclic derivative and application thereof | 浙江我武翼方药业有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-11155557-B2 | Pyrazolopyrimidine compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| EP-3255042-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC (KR) | 2020-12-30 | — | — | EP | disclosed |
| EP-3255042-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC (KR) | 2020-12-30 | — | — | EP | disclosed |
| US-20200190062-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC. (KR) | 2020-06-18 | — | — | US | disclosed |
| US-20200190062-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC. (KR) | 2020-06-18 | — | — | US | disclosed |
| US-10611754-B2 | Heterocyclic compound and pharmaceutical composition comprising same | BEYONDBIO INC. (KR) | 2020-04-07 | — | — | US | disclosed |
| US-10611754-B2 | Heterocyclic compound and pharmaceutical composition comprising same | BEYONDBIO INC. (KR) | 2020-04-07 | — | — | US | disclosed |
| US-20190345165-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-20190135786-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC. (KR) | 2019-05-09 | — | — | US | disclosed |
| US-20190135786-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC. (KR) | 2019-05-09 | — | — | US | disclosed |
| US-10227328-B2 | Heterocyclic compound and pharmaceutical composition comprising same | BEYONDBIO INC. (KR) | 2019-03-12 | — | — | US | disclosed |
| US-10227328-B2 | Heterocyclic compound and pharmaceutical composition comprising same | BEYONDBIO INC. (KR) | 2019-03-12 | — | — | US | disclosed |
| US-20180273510-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC. (KR) | 2018-09-27 | — | — | US | disclosed |
| WO-2016126085-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 비욘드바이오주식회사 | 2016-08-11 | — | — | WO | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155557-B2 | Pyrazolopyrimidine compounds and methods of use thereof | JAK2, JAK1, JAK3 | HPGD 1349/4885RECQL 2706/4885PTPN2 135/4885 |
| US-20190135786-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CDK5, CDK1, CDK4 | HPGD 561/4885RECQL 1138/4885PTPN2 1735/4885 |
| US-20190345165-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | HPGD 1349/4885RECQL 2706/4885PTPN2 135/4885 |
| US-10227328-B2 | Heterocyclic compound and pharmaceutical composition comprising same | CDK5, CDK1, CDK4 | HPGD 561/4885RECQL 1138/4885PTPN2 1735/4885 |
| US-20200190062-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CDK5, CDK3, CDK1 | HPGD 523/4885RECQL 1301/4885PTPN2 2347/4885 |
| US-20180273510-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CDK5, CDK1, CDK4 | HPGD 561/4885RECQL 1138/4885PTPN2 1735/4885 |
| US-10611754-B2 | Heterocyclic compound and pharmaceutical composition comprising same | CDK5, CDK1, CDK4 | HPGD 561/4885RECQL 1138/4885PTPN2 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.